Edgewise Therapeutics, Inc. (EWTX) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$191.41M | -20.5% |
| 2024 | -$158.83M | -38.9% |
| 2023 | -$114.36M | -59.6% |
| 2022 | -$71.66M | -65.8% |
| 2021 | -$43.22M | -151.4% |
| 2020 | -$17.19M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$191.41M | -20.5% |
| 2024 | -$158.83M | -38.9% |
| 2023 | -$114.36M | -59.6% |
| 2022 | -$71.66M | -65.8% |
| 2021 | -$43.22M | -151.4% |
| 2020 | -$17.19M | — |